Clinical Research
Filter News
Found 107,887 articles
-
Arizona is not exactly the first place one thinks of when it comes to the life sciences. But, like many states and municipalities, Arizona and Phoenix, Arizona, are working hard to grow the life science industry. According to AZBio, bioscience companies in Arizona employed 25,686 people in 2016 i...
-
One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration for its lead asset, inebilizumab.
-
Exclusive: Sweden’s Lobsor Gains U.S. Patent for Its Advanced Parkinson’s Disease Treatment
3/21/2019
Privately-held Swedish pharmaceutical company Lobsor Pharmaceuticals AB is eying the U.S. market for a potential treatment for neurodegenerative diseases such as Parkinson’s disease. -
Exscientia will use its full-stack AI drug discovery platform, Centaur Chemist, to accelerate the discovery of small molecule therapeutic drug candidates. It will focus on three of Celgene’s therapeutic programs in oncology and autoimmunity.
-
Biotech and pharma companies from across Europe and Asia provide updates on pipeline and business activities.
-
2019 Urology Care Foundation Research Scholar Awardees Announced
3/21/2019
The American Urological Association (AUA) and the Urology Care Foundation—the official foundation of the AUA—are pleased to announce the recipients of the 2019 Urology Care Foundation Research Scholar Awards.
-
ZipLine Medical Announces New Emergency Department Study Showing Significant Time and Cost Savings, and Superior Patient Satisfaction, with Laceration Closure Using Zip® Surgical Skin Closure
3/21/2019
ZipLine Medical, Inc. announced presentation of positive results from a randomized, prospective clinical study conducted at the Karolinska University Hospital in Stockholm, Sweden demonstrating both clinical and economic benefits of the Zip® Surgical Skin Closure device when used in an emergency medicine setting for lacerations.
-
Point-of-care Diagnostic for Preeclampsia shown Superior to Current Practice
3/21/2019
GestVision, Inc., a privately-held biotechnology company, applauds the diligent work of the clinical researchers who conducted the first prospective clinical study of a rapid CRD urine diagnostic for confirming or ruling out preeclampsia
-
Neuronetics, Inc. Celebrates Dr. Charles Epstein's Contributions to Magnetic Stimulation Research
3/21/2019
Emory University's 13th Annual Celebration of Technology and Innovation Honors Dr. Epstein with Start-Up of the Year Award for Pioneering Technology Utilized in NeuroStar Advanced Therapy for the Treatment of Depression
-
New Insights on an Ancient Disease and Evidence of Effective Therapy
3/21/2019
Gout has plagued human for hundreds of years but new evidence shows how to understand it better and treat it more effectively
-
Samsung Bioepis Announces Three-year Follow-up Data for Biosimilar ONTRUZANT® (trastuzumab) in Early or Locally Advanced HER2-positive Breast Cancer
3/21/2019
Three-year follow-up data show comparable overall survival between biosimilar ONTRUZANT® (trastuzumab) and reference medicine HERCEPTIN®i (trastuzumab)ii in early and locally advanced HER2-positive breast cancer
-
Research from XJTLU advances RNA modification mapping
3/21/2019
Researchers from Xi'an Jiaotong-Liverpool University have completed a high-resolution prediction of the whole-transcriptome m6A RNA modification, successfully creating the world's most accurate map of the m6A epitranscriptome.
-
JOMS study: CT scans overused in patients with dental infections
3/21/2019
Computed tomography is used excessively for scanning dental infections even though history and physical examinations can help correctly diagnose higher-risk infections before having patients undergo the scanning, which is associated with high costs and long-term potential for cancer, according to a study published in the March issue of the Journal of Oral and Maxillofacial Surgery.
-
The trial, which paired a checkpoint inhibitor and PARP inhibitor, was not likely to hit endpoints. It was the second ovarian cancer trial failure for the two companies in six months.
-
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.
-
Alexion Pharmaceuticals announced two big collaboration partnerships today. First, Alexion, headquartered in Boston, and Affibody AB, located in Solna, Sweden, signed a partnership deal to co-develop ABY-039 for Immunoglobulin G (IgG)-mediated autoimmune diseases.
-
In the cannabis sector of drug development, there is a movement happening. And Rob Davidson, chief executive officer of CURE Pharmaceuticals is making sure his company is ready for the next steps.
-
March is National Kidney Month, with March 14 designated as World Kidney Day. The kidneys are called the body’s chemical factories. Their job is to filter waste and perform specific important jobs like controlling red blood cell production and blood pressure.
-
Department of Defense Autism Research Program Funding Opportunities for Fiscal Year 2019 (FY19)
3/20/2019
The FY19 Defense Appropriation provides $7.5 million to the Department of Defense Autism Research Program to provide support for research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders.
-
Remarkable Health Launches Mobile Technology to Help Behavioral Health and DD Providers Adopt Value-driven Reimbursement Models
3/20/2019
Remarkable Health, an innovative technology partner for behavioral health and DD providers, announced today new survey data on the IT readiness of behavioral health providers for value-based reimbursement models.